Elsevier

Clinical Therapeutics

Volume 30, Issue 3, March 2008, Pages 560-571
Clinical Therapeutics

Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma

https://doi.org/10.1016/j.clinthera.2008.03.011Get rights and content

Abstract

Background: Clinical trials suggest that in patients with asthma inadequately controlled on low- to medium- dose inhaled corticosteroids (ICSs), the addition of a long-acting β-agonist such as salmeterol (SAL is more effective than the addition of montelukast (MON) or a higher-dose ICS.

Objective: This study was designed to expand on these earlier findings by comparing asthma-related health care resource utilization and costs, as well as adherence to ICSs, in children and adults with asthma receiving ICS monotherapy who either were switched to fluticasone propionate plus SAL from a single inhaler (FSC) or initiated add-on therapy with SAL from a separate inhaler or MON.

Methods: This retrospective study used an integrated managed-care database from >30 health plans. Patients were ≥5 years of age with a diagnosis of asthma (International Classification of Diseases, Ninth Revision, Clinical Modification 493.xx) and ≥2 claims for FSC, SAL, or MON. The date of first claim for the medication of interest was the index date. Patients were also required to have ≥1 claim for an ICS during the 12 months preindex and 12 months postindex. Utilization and costs of asthma-related care and adherence to ICS treatment postindex were compared using multivariate methods.

Results: After adjusting for preindex characteristics, patients receiving FSC (n = 1287) had fewer claims for short-acting β-agonists, oral corticosteroids, and lower adjusted asthma-related costs postindex compared with ICS + SAL (n = 562) and ICS + MON (n = 420). FSC patients also had greater adherence to ICS therapy. Those who received FSC had lower risks for treatment failure (defined as asthma-related emergency department visits or hospitalization or receipt of alternative study medication or oral corticosteroids during the postindex period).

Conclusion: In this health insurance claims-based study of patients with asthma inadequately controlled with an ICS alone, those who received stepped-up therapy with FSC used fewer rescue medications and had greater persistence with ICSs compared with those in whom SAL or MON was added to ICS monotherapy.

References (32)

  • PS Romano et al.

    Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives

    J Clin Epidemiol

    (1993)
  • National Asthma Education and Prevention Program

    Expert panel report 2: Guidelines for the diagnosis and management of asthma

    (1997)
  • Global strategy for asthma management and prevention

  • M Masoli et al.

    Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma

    Thorax

    (2005)
  • K Bergeron et al.

    Adherence to HAART in clinical trials vs clinical care setting

    Int Conf AIDS

    (1998)
  • DN Kiortsis et al.

    Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients

    J Clin Pharm Ther

    (2000)
  • Cited by (35)

    • Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England

      2022, Respiratory Medicine
      Citation Excerpt :

      Increasing the ICS dose puts the patient at increased risk of side effects (and their associated cost) [30,31]; monoclonal antibodies, although effective and with minimal side effects [32], are expensive and are indicated only for specific subsets of patients; and adding an oral therapy increases treatment complexity, with theophylline use complicated by a narrow therapeutic index, in that the toxic dose is only slightly above the therapeutic dose [22]. In this context, the addition of a LAMA to therapy is a sensible choice – especially as part of a SITT, given simplification of maintenance therapy to a single inhaler can be expected to optimise adherence and persistence [25–28], and is also an easier treatment option for patients than using multiple inhalers. The current analyses provide additional support to the use of add-on LAMA therapy: not only was high-dose BDP/FF/G £2323 cheaper than high-dose BDP/FF plus tiotropium, but BDP/FF/G gained 0.017 additional QALYs, resulting in the SITT being dominant.

    • Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler – Results from a non-interventional study

      2017, Respiratory Medicine
      Citation Excerpt :

      LABA and ICS can be administered via separate inhalers or combined in one inhaler. Advantages of fixed-dose ICS/LABA inhalers include greater patient convenience, an increase in patient adherence as a result of simplification of the regime [10,11] and elimination of the possibility of LABA monotherapy and its attendant risks [12]. Treatment with a fixed combination of the ICS, fluticasone propionate, and the LABA, formoterol fumarate (fluticasone propionate/formoterol fumarate [FP/FORM]), as an aerosol suspension in a hydrofluoroalkane (HFA)-based pressurised metered-dose inhaler (pMDI) is associated with greater efficacy than treatment with each its components (fluticasone or formoterol) administered as monotherapy [13–16].

    • Pulmonary vascular changes in asthma and COPD

      2014, Pulmonary Pharmacology and Therapeutics
    • Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD

      2013, Respiratory Medicine
      Citation Excerpt :

      However, this is the only study demonstrating such data, and this area requires further research. Multiple-inhaler use has been associated with higher rates of non-adherence than single-inhaler use in both asthma and COPD patients – potentially because of the increased complexity introduced by the additional inhaler(s).32,58–60 Although one study found that certain inhaler types may be associated with higher rates of adherence than others in patients with asthma receiving ICS,61 data in this area are lacking and it is important to note that individual patients will have different device preferences.

    • Comparison of effectiveness between beclomethasone dipropionate and fluticasone propionate in treatment of children with moderate asthma

      2010, World Allergy Organization Journal
      Citation Excerpt :

      This could be because of differences in pharmacokinetics and pharmacodynamics of FP and BDP 8. Although the results of our study was in agreement with some previous studies toward benefit of FP than BDP,9–11 the studies by Nong et al 12 and Karakoc et al 13 did not find any significant difference in lung function improvement and symptom scores in asthmatic children receiving either BDP or FP. However, these studied might be limited by the fact that they considered half dose of FP than BDP in their study 13.

    • Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials

      2019, The Lancet
      Citation Excerpt :

      However, the addition of tiotropium requires patients to use two different inhalers of different design with different instructions for use, and often with different dosing regimens. Such a combination is not only inconvenient for patients and health-care providers who instruct on correct inhaler use, but can negatively affect treatment adherence and persistence.6–9 A single-inhaler triple therapy consisting of an extrafine formulation (ie, with mass median aerodynamic diameter <2 μm) of the inhaled corticosteroid beclometasone dipropionate, the long-acting β2 agonist formoterol fumarate, and the long-acting muscarinic antagonist glycopyrronium (known as BDP/FF/G from hereon) delivered via a pressurised metered-dose inhaler is in development for patients with asthma.

    View all citing articles on Scopus

    Preliminary results from this study were presented at the 2005 American Thoracic Society Annual Meeting, May 23, 2005, San Diego, California; and the 2006 Annual Meeting of the American Academy of Allergy, Asthma, and Immunology, March 18–22, 2006, San Antonio, Texas.

    View full text